-
1Academic Journal
Συγγραφείς: A. S. Kalpinskiy, O. A. Mailyan, А. С. Калпинский, О. А. Маилян
Πηγή: Cancer Urology; Том 20, № 4 (2024); 75-89 ; Онкоурология; Том 20, № 4 (2024); 75-89 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: энфортумаб ведотин, metastatic bladder cancer, enfortumab vedotin, метастатический рак мочевого пузыря
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1904/1577; Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. Available at: https://gco.iarc.who.int/today; Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с.; Von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI:10.1200/JCO.2000.18.17.3068; De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI:10.1200/JCO.2011.37.3571; Bellmunt J., von der Maase H., Mead G.M. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30(10):1107–13. DOI:10.1200/JCO.2011.38.6979; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. DOI:10.1056/NEJMoa2002788; Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26. DOI:10.1056/NEJMoa1613683; Powles T., Durán I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–57. DOI:10.1016/S0140-6736(17)33297-X; Knowles M.A., Hurst C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015;15(1):25–41. DOI:10.1038/nrc3817; Loriot Y., Necchi A., Park S.H. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338–48. DOI:10.1056/NEJMoa1817323; Black P.C., Alimohamed N.S., Berman D. et al. Optimizing management of advanced urothelial carcinoma: a review of emerging therapies and biomarker-driven patient selection. Can Urol Assoc J 2020;14:E373–82. DOI:10.5489/cuaj.6458; Nadal R., Bellmunt J. Management of metastatic bladder cancer. Cancer TreatRev 2019;76:10–21. DOI:10.1016/j.ctrv.2019.04.002; Patel V.G., Oh W.K., Galsky M.D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020;70(5):404–23. DOI:10.3322/caac.21631; EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3; Flaig T.W., Spiess P.E., Abern M. et al. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(4):216–25. DOI:10.6004/jnccn.2024.0024; Tagawa S., Balar A.V., Petrylak D.P. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474–85. DOI:10.1200/JCO.20.03489; Gilead provides update on U.S. indication for Trodelvy in metastatic urothelial cancer. News release. October 18, 2024. Accessed October 18, 2024. Available at: https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer; Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI:10.1200/JCO.2008.20.5534; Bellmunt J., Fougeray R., Rosenberg J.E. et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum based chemotherapy. Ann Oncol 2013;24(6):1466–72. DOI:10.1093/annonc/mdt007; Dreicer R., Manola J., Schneider D.J. et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97(11):2743–7. DOI:10.1002/cncr.11413; McCaffrey J.A., Hilton S., Mazumdar M. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15(5):1853–7. DOI:10.1200/JCO.1997.15.5.1853; Vaughn D.J., Broome C.M., Hussain M. et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20(4):937–40. DOI:10.1200/JCO.2002.20.4.937; Sridhar S.S., Blais N., Tran B. et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. JAMA Oncol 2020;6(11):1–8. DOI:10.1001/jamaoncol.2020.3927; Meric-Bernstam F., Makker V., Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47–58. DOI:10.1200/JCO.23.02005; Challita-Eid P.M., Satpayev D., Yang P. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76:3003–13. DOI:10.1158/0008-5472.CAN-15-1313; Hoffman-Censits J.H., Lombardo K.A., Parimi V. et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol 2021;29(8):619–25. DOI:10.1097/PAI.0000000000000938; Zhang Y., Liu S., Wang L. et al. A novel PI3K/AKT signaling axis mediates nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett 2016;375:179–89. DOI:10.1016/j.canlet.2016.02.049; Zhang Y., Zhang J., Shen Q. et al. High expression of nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett 2018;15:8789–95. DOI:10.3892/ol.2018.8365; Tomiyama E., Fujita K., Rodriguez Pena M.D.C. et al. Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci 2020;21(15):5390. DOI:10.3390/ijms21155390; Mantia C.M., Sonpavde G. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther 2022;22(5):449–55. DOI:10.1080/14737140.2022.2069563; Инструкция к препарату Падцев Онко. Доступно по: https://www.vidal.ru/drugs/padtsev-onko; Rosenberg J., Sridhar S.S., Zhang J. et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 2020;38:1041–9. DOI:10.1200/JCO.19.02044; Rosenberg J.E., O’Donnell P.H., Balar A.V. et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592–600. DOI:10.1200/JCO.19.01140; Yu E.Y., Petrylak D.P., O’Donnell P.H. et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22:872–82. DOI:10.1016/S1470-2045(21)00094-2; Balar A.V., McGregor B.A., Rosenberg J.E. et al. EV-201 cohort 2: enfortumab vedotin in cisplatin-i neligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. J Clin Oncol 2021;39(suppl):394.; Powles T., Rosenberg J.E., Sonpavde G.P. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125–1135. DOI:10.1056/NEJMoa2035807; Rosenberg J.E., Powles T., Sonpavde G.P. et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023;34(11):1047–54. DOI:10.1016/j.annonc.2023.08.016; Rosenberg J.E., Mamtani R., Sonpavde G.P. et al. Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy. Eur Urol 2024;85(6):574–85. DOI:10.1016/j.eururo.2024.01.007; Koshkin V.S., Henderson N., James M. et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 2022;128(6):1145–345. DOI:10.1002/cncr.34057; https://oncourology.abvpress.ru/oncur/article/view/1904
-
2
-
3Academic Journal
Συγγραφείς: A. A. Gritskevich, A. Yu. Popov, I. G. Rusakov, E. K. Vozniy, V. A. Makarov, D. I. Gridnev, T. P. Baitman, S. V. Mishugin, I. V. Novikova, S. V. Khromova, А. А. Грицкевич, А. Ю. Попов, И. Г. Русаков, Э. К. Возный, В. А. Макаров, Д. И. Гриднев, Т. П. Байтман, С. В. Мишугин, И. В. Новикова, С. В. Хромова
Πηγή: Meditsinskiy sovet = Medical Council; № 9 (2022); 95-103 ; Медицинский Совет; № 9 (2022); 95-103 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: клинический случай, metastatic bladder cancer, vinflunin, chemotherapy, second line, clinical report, метастатический рак мочевого пузыря, винфлунин, химиотерапия, вторая линия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/6922/6219; Каприн А.Д., Старинский В.В., Шахзадова А.О. (ред.).Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.; 2021. 252 с. Режим доступа: https://oncology-association.ru/wp-content/uploads/2021/11/zis-2020-elektronnaya-versiya.pdf?ysclid=l3badk8twu.; Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet. Oncology. 2011;12(3):211—214. https://doi.org/10.1016/S1470-2045(10)70275-8.; Galsky M.D., Hahn N.M., Rosenberg J., Sonpavde G., Hutson T., Oh W.K. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy.J Clin Oncol. 2011;29(17):2432-2438. https://doi.org/10.1200/JCO.2011.34.8433.; Hussain S.A., Palmer D.H., Lloyd B., Collins S.I., Barton D., Ansari J., James N. D. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012;3(4):855-859. https://doi.org/10.3892/ol.2012.563.; Hussain S.A., Stocken D.D., Riley P., Palmer D.H., Peake D.R., Geh J.I. et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91(5):844-849. https://doi.org/10.1038/sj.bjc.6602112.; Sternberg C.N., Calabro F., Pizzocaro G., Marini L., Schnetzer S., Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92(12):2993-2998. https//doi.org/10.1002/1097-0142(20011215)92:123.0.co;2-2.; Meluch A.A., Greco F.A., Burris H.A. 3rd, O'Rourke T., Ortega G., Steis R.G. et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001;19(12):3018-3024. https://doi.org/10.1200/JCO.2001.19.12.3018.; Calabro F., Lorusso V., Rosati G., Manzione L., Frassineti L., Sava T. et al. Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma. Cancer. 2009;115(12):2652-2659. https://doi.org/10.1002/cncr.24313.; De Santis M., Wiechno P.J., Bellmunt J., Lucas C., Su W.C., Albiges L. et al. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol. 2016;27(3):449-454. https//doi.org/10.1093/annonc/mdv609.; Galsky M.D., Arija J., Bamias A., Davis I.D., De Santis M., Kikuchi E. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre,randomised,placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547-1557. https//doi.org/10.1016/S0140-6736(20)30230-0.; Powles T., Csoszi T., Ozguroglu M., Matsubara N., Geczi L., Cheng S.Y. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(7):931-945. https//doi.org/10.1016/S1470-2045(21)00152-2.; Powles T., van der Heijden M.S., Castellano D., Galsky M.D., Loriot Y., Petrylak D.P. et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574-1588. https//doi.org/10.1016/S1470-2045(20)30541-6.; Oing C., Rink M., Oechsle K., Seidel C., von Amsberg G., Bokemeyer, C. Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature. J Urol. 2016;195(2):254-263. https//doi.org/10.1016/j.juro.2015.06.115.; Raggi D., Miceli R., Sonpavde G., Giannatempo P., Mariani L., Galsky M.D. et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27(1):49-61. https//doi.org/10.1093/annonc/mdv509.; Albers P., Park S.I., Niegisch G., Fechner G., Steiner U., Lehmann J. et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22(2):288-294. https://doi.org/10.1093/annonc/mdq398.; Fechner G., Siener R., Reimann M., Kobalz L., Albers P. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract. 2006;60(1):27-31. https//doi.org/10.1111/j.1742-1241.2005.00663.x.; Bellmunt J., Theodore C., Demkov T., Komyakov B., Sengelov L., Daugaard G. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27(27):4454-4461. https//doi.org/10.1200/JCO.2008.20.5534.; Жавлор: новые возможности в терапии больных метастатическим раком мочевого пузыря. Х Юбилейный конгресс Российского общества онкоурологов. Сателлитный симпозиум компании Pierre Fabre. Эффективная фармакотерапия. 2015;(3):34-38. Режим доступа: https://umedp.ru/upload/iblock/6a5/onko_03_2015.pdf.; Castellano D., Puente J., de Velasco G., Chirivella I., Lopez-Criado P., Mohedano N. et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer. 2014;14:779. https://doi.org/10.1186/1471-2407-14-779.; Medioni J., Di Palma M., Guillot A., Spaeth D., Theodore C. Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study. BMC Cancer. 2016;16:217. https://doi.org/10.1186/s12885-016-2262-9.; Retz M., de Geeter P., Goebell P.J., Matz U., de Schultz W., Hegele A. Vinflunine in routine clinical practice for the treatment of advanced or metastatic urothelial cell carcinoma - data from a prospective, multicenter experience. BMC Cancer. 2015;15:455. https://doi.org/10.1186/s12885-015-1434-3.; Волкова М.И., Черняев В.А., Матвеев В.Б., Алексеев Б.Я., Нюшко К.М., Болотина Л.В. и др. Эффективность и безопасность винфлунина во 2-й линии терапии у больных распространенным переходно-клеточным раком мочевых путей в клинической практике. Онкоурология. 2016;(3):74-81. https://doi.org/10.17650/1726-9776-2016-12-3-74-81.
-
4Academic Journal
Συγγραφείς: Denysov, S.U., Leonenko, O.O., Prokopiv, K.I., Leonenko, A.M.
Πηγή: Urologiya; Том 24, № 3 (2020)
Урология; Том 24, № 3 (2020)
Урологія; Том 24, № 3 (2020)Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, метастатичний рак сечового міхура, хіміоемболізація, макрогематурія, мікросфери, ангіографія, metastatic bladder cancer, chemoembolization, macrohematuria, microspheres, angiography, метастатический рак мочевого пузыря, химиоэмболизация, макрогематурия, микросферы, ангиография, 3. Good health
Περιγραφή αρχείου: application/pdf
-
5Academic Journal
Συγγραφείς: Грицкевич А.А., Байтман Т.П., Мишугин С.В., Попов А.Ю., Оганян В.А., Русаков И.Г., Костин А.А.
Πηγή: Meditsinskiy Sovet
Θεματικοί όροι: urothelial carcinoma, Metastatic bladder cancer, immune checkpoint inhibitors, atezolizumab, уротелиальная карцинома, метастатический рак мочевого пузыря, ингибиторы иммунных контрольных точек, атезолизумаб
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/98175/
-
6Academic Journal
Συγγραφείς: Грицкевич А.А., Попов А.Ю., Русаков И.Г., Возный Э.К., Макаров В.А., Гриднев Д.И., Байтман Т.П., Мишугин С.В., Новикова И.В., Хромова С.В.
Πηγή: Meditsinskiy Sovet
Θεματικοί όροι: urothelial carcinoma, Metastatic bladder cancer, vinflunin, chemotherapy, second line, Clinical report, уротелиальная карцинома, метастатический рак мочевого пузыря, винфлунин, химиотерапия, вторая линия, клинический случай
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/86557/